Publications
Below you can find a list of our published research.
Below you can find a list of our published research.
511 results
Cited 32 times since 2013 (2.9 per year) source: EuropePMC
Clinical cancer research : an official journal of the American Association for Cancer Research, Volume 19, Issue 15, 25 4 2013, Pages 4163-4173 Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [¹¹C]docetaxel and positron emission tomography. van der Veldt AA, Lubberink M, Mathijssen RH, Loos WJ, Herder GJ, Greuter HN, Comans EF, Rutten HB, Eriksson J, Windhorst AD, Hendrikse NH, Postmus PE, Smit EF, Lammertsma AA
Purpose: Pharmacokinetics of docetaxel can be measured in vivo using positron emission tomography (PET) and a microdose of radiolabeled docetaxel ([(11)C]docetaxel). The objective of this study was to investigate whether a [(11)C]docetaxel PET microdosing study could predict tumor uptake of therapeutic doses of docetaxel. Experimental design: Docetaxel-naïve lung cancer patients underwent 2 [(11)C]docetaxel PET scans; one after bolus injection of [(11)C]docetaxel and another during combined infu... Abstract
Cited 10 times since 2013 (0.9 per year) source: EuropePMC
Virchows Archiv : an international journal of pathology, Volume 462, Issue 5, 3 1 2013, Pages 547-556 Complete pathological response is predictive for clinical outcome after tri-modality therapy for carcinomas of the superior pulmonary sulcus. Blaauwgeers JL, Kappers I, Klomp HM, Belderbos JS, Dijksman LM, Smit EF, Postmus PE, Paul MA, Oosterhuis JW, Hartemink KJ, Vos CG, Burgers JA, Dahele M, Phernambucq EC, Witte BI, Thunnissen E
The objective was to define the relationship between histopathological changes after pre-operative chemo-radiotherapy (CRT) and clinical outcome following tri-modality therapy in patients with superior sulcus tumours. A retrospective analysis of tumour material was performed in a series of 46 patients who received tri-modality therapy between 1997 and 2007. Median follow-up was 34 months (5-154). Pathological complete response (pCR) was present in 20/46 tumours (43 %). The most common RECIST sco... Abstract
Cited 2 times since 2013 (0.2 per year) source: EuropePMC
Oncology letters, Volume 5, Issue 5, 19 3 2013, Pages 1591-1594 Can quantifying free-circulating DNA in plasma be used to identify subjects with high-grade pre-invasive endobronchial lesions? VAN Boerdonk RA, Brokx HA, Lee P, Kooi C, Postmus PE, Snijders PJ, Grünberg K, Thunnissen E, Sutedja TG, Daniels JM, Heideman DA
Increased concentrations of free-circulating plasma DNA (cpDNA) are observed in patients with invasive cancer, including lung cancer. Whether cpDNA levels are elevated in subjects with high-grade pre-invasive lesions of lung squamous cell carcinoma (SqCC) and whether its detection may be of value for identifying subjects at the highest risk of developing lung SqCC is currently unknown. The present study assessed cpDNA levels in subjects with high- and low-grade pre-invasive squamous endobronchia... Abstract
Respiration; international review of thoracic diseases, Volume 85, Issue 5, 13 2 2013, Pages 365-366 Ventilator-associated pneumothorax: drainage is not always necessary. Postmus PE
Cited 21 times since 2013 (1.9 per year) source: EuropePMC
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, Volume 12, Issue 5, 27 4 2013, Pages 454-460 Exhaled molecular profiles in the assessment of cystic fibrosis and primary ciliary dyskinesia. Paff T, van der Schee MP, Daniels JM, Pals G, Postmus PE, Sterk PJ, Haarman EG
Background: Early diagnosis and monitoring of disease activity are essential in cystic fibrosis (CF) and primary ciliary dyskinesia (PCD). We aimed to establish exhaled molecular profiles as the first step in assessing the potential of breath analysis. Methods: Exhaled breath was analyzed by electronic nose in 25 children with CF, 25 with PCD and 23 controls. Principle component reduction and canonical discriminant analysis were used to construct internally cross-validated ROC curves. Results: C... Abstract
Cited 28 times since 2012 (2.5 per year) source: EuropePMC
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, Volume 32, Issue 2, 9 2 2012, Pages 231-240 Right ventricular oxygen supply parameters are decreased in human and experimental pulmonary hypertension. Ruiter G, Ying Wong Y, de Man FS, Louis Handoko M, Jaspers RT, Postmus PE, Westerhof N, Niessen HW, van der Laarse WJ, Vonk-Noordegraaf A
Background: In pulmonary arterial hypertension (PAH), high right ventricular (RV) power output requires increased myocardial oxygen consumption. Oxygen supply, however, does not increase in proportion. It is unknown what cellular mechanisms underlie this lack of adaptation. We therefore determined oxygen supply parameters in RV tissue slices of deceased PAH patients and compared them with RV tissue of patients who died from left ventricular myocardial infarction (MI). Because autopsy tissue only... Abstract
Cited 69 times since 2012 (6.1 per year) source: EuropePMC
Clinical cancer research : an official journal of the American Association for Cancer Research, Volume 19, Issue 1, 7 1 2012, Pages 183-193 Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status. Bahce I, Smit EF, Lubberink M, van der Veldt AA, Yaqub M, Windhorst AD, Schuit RC, Thunnissen E, Heideman DA, Postmus PE, Lammertsma AA, Hendrikse NH
Purpose: To evaluate whether, in patients with non-small cell lung carcinoma (NSCLC), tumor uptake of [(11)C]erlotinib can be quantified and imaged using positron emission tomography and to assess whether the level of tracer uptake corresponds with the presence of activating tumor EGF receptor (EGFR) mutations. Experimental design: Ten patients with NSCLCs, five with an EGFR exon 19 deletion, and five without were scanned twice (test retest) on the same day with an interval of at least 4 hours.... Abstract
Cited 57 times since 2012 (5 per year) source: EuropePMC
Chest, Volume 142, Issue 5, 1 1 2012, Pages 1166-1174 Ventilatory and cardiocirculatory exercise profiles in COPD: the role of pulmonary hypertension. Boerrigter BG, Bogaard HJ, Trip P, Groepenhoff H, Rietema H, Holverda S, Boonstra A, Postmus PE, Westerhof N, Vonk-Noordegraaf A
Background: Pulmonary hypertension (PH) is a well-recognized complication of COPD. The impact of PH on exercise tolerance is largely unknown. We evaluated and compared the circulatory and ventilatory profiles during exercise in patients with COPD without PH, with moderate PH, and with severe PH. Methods: Forty-seven patients, GOLD (Global Initiative for Chronic Obstructive Lung Disease)stages II to IV, underwent cardiopulmonary exercise testing and right-sided heart catheterization at rest and d... Abstract
Cited 15 times since 2012 (1.3 per year) source: EuropePMC
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Volume 7, Issue 10, 1 1 2012, Pages 1522-1527 Negative NKX2-1 (TTF-1) as temporary surrogate marker for treatment selection during EGFR-mutation analysis in patients with non-small-cell lung cancer. Vincenten J, Smit EF, Vos W, Grünberg K, Postmus PE, Heideman DA, Snijders PJ, Meijer G, Kuik J, Witte BI, Thunnissen E
Introduction: In the past decade, major progress has been made toward personalized medical treatment of non-small-cell lung cancer (NSCLC) through the discovery of epithelial growth factor receptor (EGFR) mutations. However, mutation analysis takes extra time and additional costs in the diagnostic evaluation of lung cancer patients. It has been hypothesized that EGFR mutations are restricted to terminal respiratory unit -type adenocarcinoma expressing thyroid transcription factor-1 (official sym... Abstract
Cited 184 times since 2012 (15.8 per year) source: EuropePMC
American journal of respiratory and critical care medicine, Volume 186, Issue 8, 2 1 2012, Pages 780-789 Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. de Man FS, Tu L, Handoko ML, Rain S, Ruiter G, François C, Schalij I, Dorfmüller P, Simonneau G, Fadel E, Perros F, Boonstra A, Postmus PE, van der Velden J, Vonk-Noordegraaf A, Humbert M, Eddahibi S, Guignabert C
Rationale: Patients with idiopathic pulmonary arterial hypertension (iPAH) often have a low cardiac output. To compensate, neurohormonal systems such as the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system are up-regulated, but this may have long-term negative effects on the progression of iPAH. Objectives: Assess systemic and pulmonary RAAS activity in patients with iPAH and determine the efficacy of chronic RAAS inhibition in experimental PAH. Methods: We collecte... Abstract
Cited 1 times since 2012 (0.1 per year) source: EuropePMC
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Volume 7, Issue 8, 1 1 2012, Pages e3-5 An 82-year-old woman with small-cell lung cancer: relapse after 9 years or a new primary? Groenendijk MR, Thunnissen E, Ylstra B, van de Wiel MA, Eijk PP, Paul MA, Smit EF, Postmus PE
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Volume 7, Issue 8, 1 1 2012, Pages e6-7 Benefit of a second opinion for lung cancer: no recurrent disease, but infection. Schook RM, Smit EF, Postmus PE, Hartemink KJ, Paul MA
Cited 16 times since 2012 (1.4 per year) source: EuropePMC
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Volume 7, Issue 8, 1 1 2012, Pages 1271-1275 Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomes. Phernambucq EC, Hartemink KJ, Smit EF, Paul MA, Postmus PE, Comans EF, Senan S
Introduction: Commonly reported complications after concurrent chemoradiotherapy (CCRT) in patients with stage III non-small-cell lung cancer (NSCLC) include febrile neutropenia, radiation esophagitis, and pneumonitis. We studied the incidence of tumor cavitation and/or "tumor abscess" after CCRT in a single-institutional cohort. Methods: Between 2003 and 2010, 87 patients with stage III NSCLC underwent cisplatin-based CCRT and all subsequent follow-up at the VU University Medical Cent... Abstract
Cited 52 times since 2012 (4.4 per year) source: EuropePMC
Cancer treatment reviews, Volume 39, Issue 3, 14 2 2012, Pages 252-260 Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). Langer CJ, Mok T, Postmus PE
The prognosis for patients with relapsed/progressive non-small cell lung cancer (NSCLC) remains poor. For first-line therapy, a number of platinum-based regimens are standard; second-line therapies include single-agent docetaxel, pemetrexed, and erlotinib. Treatment options for patients whose tumors have failed to respond to two or more conventional chemotherapy regimens are limited, with erlotinib, which targets the epidermal growth factor receptor, and crizotinib, which targets EML4/ALK, the o... Abstract
Cited 14 times since 2012 (1.2 per year) source: EuropePMC
Journal of clinical pathology, Volume 65, Issue 6, 29 5 2012, Pages 541-545 Prolonged sampling of spontaneous sputum improves sensitivity of hypermethylation analysis for lung cancer. Hubers AJ, Heideman DA, Herder GJ, Burgers SA, Sterk PJ, Kunst PW, Smit HJ, Postmus PE, Witte BI, Duin S, Snijders PJ, Smit EF, Thunnissen E
Aims: The adequacy of lung cancer diagnosis with sputum cytology depends on duration of sputum sampling. The aim of this methodological study was to determine whether the hypermethylation detection rate of RASSF1A, adenomatous polyposis coli (APC) and cytoglobin (CYGB) is influenced by the duration of sputum collection. Methods: Prospective sputum samples were collected from 53 lung cancer patients and 47 chronic obstructive pulmonary disease patients as controls. Subjects collected spontaneous... Abstract
The oncologist, Volume 17, Issue 3, 21 3 2012, Pages 463-465 Reflections on the 14th World Conference on Lung Cancer: A European Perspective. Senan S, Postmus PE
Cited 204 times since 2012 (16.7 per year) source: EuropePMC
Cancer cell, Volume 21, Issue 1, 1 1 2012, Pages 82-91 Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, Hendrikse NH, Eriksson J, Windhorst AD, Postmus PE, Verheul HM, Serné EH, Lammertsma AA, Smit EF
Current strategies combining anti-angiogenic drugs with chemotherapy provide clinical benefit in cancer patients. It is assumed that anti-angiogenic drugs, such as bevacizumab, transiently normalize abnormal tumor vasculature and contribute to improved delivery of subsequent chemotherapy. To investigate this concept, a study was performed in non-small cell lung cancer (NSCLC) patients using positron emission tomography (PET) and radiolabeled docetaxel ([(11)C]docetaxel). In NSCLC, bevacizumab re... Abstract
Cited 7 times since 2011 (0.6 per year) source: EuropePMC
The Journal of rheumatology, Volume 39, Issue 1, 15 3 2011, Pages 100-105 Pulmonary arterial hypertension in systemic sclerosis is associated with profound impairment of microvascular endothelium-dependent vasodilatation. Hofstee HM, Voskuyl AE, Vonk Noordegraaf A, Smulders YM, Postmus PE, Dijkmans BA, Serné EH
Objective: Impaired microvascular function may contribute to organ complications in patients with systemic sclerosis (SSc). We investigated whether SSc patients with and without pulmonary arterial hypertension (PAH) show a graded impairment of microvascular function compared to healthy controls. Methods: Twenty-two patients with SSc and 22 controls were studied. All patients underwent right heart catheterization; 6 had no PAH (SSc-nonPAH) and 16 had PAH (SSc-PAH). Acetylcholine (ACh)-mediated en... Abstract
Cited 110 times since 2011 (8.9 per year) source: EuropePMC
Circulation. Heart failure, Volume 5, Issue 1, 9 2 2011, Pages 97-105 Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. de Man FS, Handoko ML, van Ballegoij JJ, Schalij I, Bogaards SJ, Postmus PE, van der Velden J, Westerhof N, Paulus WJ, Vonk-Noordegraaf A
Background: In pulmonary arterial hypertension (PH), sympathetic adrenergic activity is highly elevated. Sympathetic overactivity is a compensatory mechanism at first, but might be detrimental for cardiac function in the long run. We therefore investigated whether chronic low-dose treatment with bisoprolol (a cardioselective β-blocker) has beneficial effects on cardiac function in experimental PH. Methods and results: PH was induced in rats by a single injection of monocrotaline (60 mg/kg). Pres... Abstract
Cited 85 times since 2011 (6.9 per year) source: EuropePMC
British journal of cancer, Volume 105, Issue 12, 1 1 2011, Pages 1912-1919 Renal cancer and pneumothorax risk in Birt-Hogg-Dubé syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families. Houweling AC, Gijezen LM, Jonker MA, van Doorn MB, Oldenburg RA, van Spaendonck-Zwarts KY, Leter EM, van Os TA, van Grieken NC, Jaspars EH, de Jong MM, Bongers EM, Johannesma PC, Postmus PE, van Moorselaar RJ, van Waesberghe JH, Starink TM, van Steensel MA, Gille JJ, Menko FH
Background: Birt-Hogg-Dubé (BHD) syndrome is an autosomal dominant condition caused by germline FLCN mutations, and characterised by fibrofolliculomas, pneumothorax and renal cancer. The renal cancer risk, cancer phenotype and pneumothorax risk of BHD have not yet been fully clarified. The main focus of this study was to assess the risk of renal cancer, the histological subtypes of renal tumours and the pneumothorax risk in BHD. Methods: In this study we present the clinical data of 115 FLCN mut... Abstract